文献速递外周动脉疾病

股腘动脉病变间歇性跛行患者腔内治疗的24个月结局:TALENT注册研究

Clinical outcome of endovascular therapy for femoropopliteal artery lesions in patients with intermittent claudication: Twenty-four-month outcomes from the TALENT registry.
PubMed 文献 · J Vasc Surg · 2025-11-21

基于TALENT前瞻性多中心注册研究,回顾性分析980例(1010条肢体)间歇性跛行患者股腘动脉腔内治疗后的24个月结局。结果显示累积CD-TLR率为7.15%,进展为CLTI仅2.20%,MALE和MACE发生率分别为7.59%和2.04%,全因死亡率为5.85%,VascuQOL评分持续改善。

要点

  • 股腘动脉腔内治疗间歇性跛行24个月结果可接受,CD-TLR率7.15%,进展为CLTI仅2.20%。
  • 慢性肾功能不全、TASC II C/D病变及既往下肢干预史是CD-TLR独立危险因素。
  • 女性、TASC II C/D病变及足部流出道差是24个月内进展为CLTI的独立危险因素。

核心结论

  • 对生活方式受限的间歇性跛行患者,股腘动脉腔内治疗的24个月临床结局可接受,健康相关生活质量持续改善。

研究设计与样本

  • 中位随访时间24个月(四分位距24-36个月)。

主要发现

  • 24个月时累积CD-TLR发生率为7.15%(95%CI 5.45%-8.85%),进展为CLTI的肢体仅2.20%(95%CI 1.18%-3.22%)。
  • MALE发生率为7.59%(95%CI 5.85%-9.34%),MACE发生率为2.04%(95%CI 1.10%-2.98%)。
  • 全因死亡率为5.85%(95%CI 4.29%-7.41%),VascuQOL评分随访期间持续改善(3.17±0.84 vs 5.71±1.19;P < .001)。
  • Cox回归显示慢性肾功能不全(肾小球滤过率<30 mL/min/1.73 m2)、TASC II C/D股腘病变及既往下肢干预史是CD-TLR独立危险因素。
  • 女性、TASC II C/D股腘病变及足部流出道差(足部流出道评分=2-3)是24个月内进展为CLTI的独立危险因素;慢性肾功能不全和TASC II C/D病变是MALE独立危险因素;慢性肾功能不全和慢性阻塞性肺疾病是MACE独立危险因素。

临床怎么用

  • 对于间歇性跛行患者,股腘动脉腔内治疗可考虑作为改善生活质量的选项,但需评估慢性肾功能不全、TASC II C/D病变等风险因素。
  • 术前应关注肾功能、病变TASC分级、足部流出道及既往干预史,以识别CD-TLR和CLTI进展高危患者。

局限性

  • 本研究为回顾性分析,尽管数据来自前瞻性注册研究,仍可能存在选择偏倚和信息偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to assess the 24-month clinical outcome of endovascular therapy (EVT) for femoropopliteal (FP) lesions in patients with lifestyle-limiting claudication in a current real-world setting. METHODS: We retrospectively analyzed data from a clinical database formed by TALENT (Impact Of Tibial Run Off On Clinical Outcome Of Endovascular Therapy In Femoropopliteal Lesions), a prospective, multicenter patient registry. We selected 980 patients (1010 limbs) with symptomatic intermittent claudication (IC) undergoing FP intervention from the TALENT registry between December 1, 2020, and May 1, 2023. The observational end points included the incidence of clinically driven target lesion revascularization (CD-TLR), major adverse limb events (MALEs), major adverse cardiovascular events (MACEs), all-cause of mortality, progression to chronic limb threatening ischemia (CLTI), and changes in self-reported quality-of-life (QOL) measures (Vascular Quality of Life 25). Prognostic predictors for MALE, MACE, CD-TLR, and progression to CLTI were elucidated by Cox proportional hazard regression analysis. RESULTS: A total of 1010 targeted limbs in 980 patients with IC treated with EVT were included in this study. The median follow-up time was 24 months (interquartile range, 24-36 months). At the 24-month follow-up, the cumulative incidence of CD-TLR was 7.15% (95% confidence interval [CI], 5.45%-8.85%), whereas progression to CLTI occurred in only 2.20% of limbs (95% CI, 1.18%-3.22%). Incidence of MALE and MACE were 7.59% (95% CI, 5.85%-9.34%) and 2.04% (95% CI, 1.10%-2.98%), respectively. The all-cause of mortality rate was 5.85% (95% CI, 4.29%-7.41%) and VascuQOL scores showed sustained improvement throughout the follow-up period (3.17 ± 0.84 vs 5.71 ± 1.19; P < .001). Cox regression analysis identified chronic renal insufficiency (CRI) (defined as a glomerular filtration rate of <30 mL/min/1.73 m2), Trans-Atlantic Inter-Society Consensus Document (TASC) II C/D FP lesions, and a history of previous lower extremity intervention as independent risk factors for CD-TLR. Female sex, TASC II C/D FP lesions, and poor pedal runoff (pedal runoff score = 2-3) were identified as independent risk factors for progression to CLTI within 24 months. CRI and TASC II C/D FP lesions were independent risk factors for MALEs. CRI and chronic obstructive pulmonary disease were independent risk factors for MACEs within 24 months. CONCLUSIONS: The 24-month clinical outcomes of EVT for FP lesions in patients with lifestyle-limiting IC demonstrated acceptable results, with sustained enhancements in health-related QOL.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Wang Y, Gan S, He C, et al. Clinical outcome of endovascular therapy for femoropopliteal artery lesions in patients with intermittent claudication: Twenty-four-month outcomes from the TALENT registry. J Vasc Surg. 2025. PMID: 41276094. doi:10.1016/j.jvs.2025.11.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。